Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent reinforces the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. According to the company, the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders.
The patent grant marks a significant milestone for Greenland Mines as it advances its biotech division. The Klotho protein, known for its anti-aging properties, has shown promise in preclinical studies for neuroprotection and muscle function. By securing intellectual property rights in Australia, the company now has broader protection for its gene therapy approach, which aims to deliver the Klotho gene to patients. This could potentially slow or halt the progression of neurodegenerative diseases like ALS. The patent covers not only the gene therapy constructs but also the methods of delivery, including viral vectors and non-viral systems, providing a comprehensive shield for the technology.
Greenland Mines’ KLTO-202 program is at the forefront of this effort, focusing on ALS, a devastating disease with limited treatment options. The company believes that the Klotho gene therapy could address the underlying pathology of ALS by protecting motor neurons and reducing inflammation. The patent validation in Australia, a key market for medical research, could accelerate partnerships and funding opportunities. Moreover, it strengthens the company’s position in the competitive gene therapy landscape, where intellectual property is a critical asset.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining and Biotech. The mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The biotech division includes the Klotho gene therapy platform, with KLTO-202 as its primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The patent announcement is a positive signal for investors and the medical community. For further details, the full press release is available at https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://nnw.fm/GRML.
